Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE - CIMA-AEMPS Drug Approval Details

Approvals/CIMA-AEMPS/REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE

Approved

STANDARD

REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE

Bristol-Myers Squibb Pharma Eeig🇪🇸 Spanish Agency of Medicines and Medical Devices

Approval Date: Aug 17, 2020
Approval ID: c87b7d21e287476a
Company: Bristol-Myers Squibb Pharma Eeig
Type: Standard

Approval Details

Approval Id: c87b7d21e287476a
Drug Cima Aemps Name: REBLOZYL 25 MG POLVO PARA SOLUCION INYECTABLE
Register Number: 1201452001
Holder Company Name: Bristol-Myers Squibb Pharma Eeig
Marketing Company Name: Bristol Myers Squibb S.A.
Holder Company Detail Path: /organization/bristol-myers-squibb-pharma-eeig
Authorization Date: 2020-08-17
Dosage Form: POLVO PARA SOLUCIÓN INYECTABLE
Dose: 25 mg
Route Of Administration: VÍA SUBCUTÁNEA
Prescription Type: Uso Hospitalario
Commercialized: Yes
Company Name: Bristol-Myers Squibb Pharma Eeig
Company Detail Path: /organization/bristol-myers-squibb-pharma-eeig

Company Information

Pharmaceutical Company Name: Bristol-Myers Squibb Pharma EEIG
Country Name: Ireland

Active Ingredients

LUSPATERCEPT

25 mg

Approved

Quick Info

Agency

CIMA-AEMPS

Country

🇪🇸

Approval Date

Aug 17, 2020

Approval ID

c87b7d21e287476a

Type

Standard

Back to CIMA-AEMPS Approvals